Indoco Remedies AAQS
The The AAQS of Indoco Remedies (INDOCO.NS) as of Oct 18, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
2
YoY
0.00%
Last updated:
Indoco Remedies has a current AAQS of 2.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Indoco Remedies in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Indoco Remedies in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Indoco Remedies AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2019
2.00 INR
Jan 1, 2020
2.00 INR
Jan 1, 2021
2.00 INR
Jan 1, 2022
2.00 INR
Jan 1, 2023
2.00 INR
Jan 1, 2024
2.00 INR
Jan 1, 2025
2.00 INR
Jan 1, 2026
2.00 INR
| YEAR | AAQS | YoY |
|---|---|---|
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | 0.00% | |
| 2 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Indoco Remedies Stock analysis
What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Indoco Remedies stock
The AAQS of Indoco Remedies is 2 in 2026.
On Eulerpool you can find the complete historical development of The AAQS Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Indoco Remedies
All Key Metrics — Indoco Remedies
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth